Multidisciplinary Thoracic Oncology Conference 2026: Advances in Lung Cancer, Thoracic Malignancies, Immunotherapy, and Precision Medicine | Los Angeles  conference hero image

Multidisciplinary Thoracic Oncology Conference 2026: Advances in Lung Cancer, Thoracic Malignancies, Immunotherapy, and Precision Medicine | Los Angeles

Accreditation: 5.75 Nursing Contact Hours | 5.75 ABIM MOC II | 5.75 AMA PRA Category 1 Credit™ | 5.75 ACPE Pharmacy

Venue: Omni Los Angeles Hotel at California Plaza, 251 S Olive St , Los Angeles, CA , 90012

Start Date:
Register for Conference

Official conference page for Multidisciplinary Thoracic Oncology Conference 2026: Advances in Lung Cancer, Thoracic Malignancies, Immunotherapy, and Precision Medicine | Los Angeles .

About Multidisciplinary Thoracic Oncology Conference 2026: Advances in Lung Cancer, Thoracic Malignancies, Immunotherapy, and Precision Medicine | Los Angeles

Conference
Conference attendees

Overview

Trusted by Thousands of Attendees
Across Our Events

Caroline Maxwell
18+

Faculty and committee

Conference program and agenda

Agenda

Saturday, November 7th, 2026

All timings are in Pacific Time (PDT, GMT-07:00) time.

07:00 AM - 08:00 AMRegistration, Breakfast, & Exhibits
08:00 AM - 08:05 AMWelcome & Opening Remarks
08:05 AM - 09:35 AMSession 1: Role of Innovation in Lung Cancer: Biomarkers, AI, At-risk populations, Risk Factors

Session Chair: Kathryn Gold, MD

08:05 AM - 08:20 AM

Role of Food and Other Carcinogens in Lung Cancer Robert Hsu, MD

08:20 AM - 08:35 AM

Lung Cancer Detection in Never Smokers Miguel Angel Villalona-Calero, MD

08:35 AM - 08:50 AM

AI in Detecting Early Lung Cancer and Recurrence

08:50 AM - 09:05 AM

Role of ctDNA in Early Stage Lung Cancer

09:05 AM - 09:15 AM

Case Presentation

09:15 AM - 09:35 AM

Case-based Panel Discussion

Moderators:

Kathryn Gold, MD

Panelists:

Robert Hsu, MD; Miguel Angel Villalona-Calero, MD

09:35 AM - 10:20 AMSession 2: Updates on Novel Targets & Treatments in Oncogene Driven Lung Cancer

09:35 AM - 09:45 AM

Insights into ADCs

09:45 AM - 09:55 AM

Novel Targeted Treatment Strategies Kamya Sankar, MD

09:55 AM - 10:05 AM

Updates on IO treatments

10:05 AM - 10:20 AM

Panel Discussion

Panelists:

Kamya Sankar, MD

10:20 AM - 11:05 AMBreak & Product Theater Sponsored by Regeneron (Non-CME Accredited)
11:05 AM - 12:35 PMSession 3: Multidisciplinary Tumor Board in Advanced Stage NSCLC

Session Chair: Ravi Salgia , MD

11:05 AM - 11:20 AM

Stage IIIA Percy Lee, MD

11:20 AM - 11:35 AM

Stage IIIB/IIIC

11:35 AM - 11:50 AM

Stage IV Oligometastatic Disease Jason Ye, MD

11:50 AM - 12:05 PM

Stage IV Polymetastatic Disease Arter Liao Zhaohui, MD

12:05 PM - 12:15 PM

Case Presentation Ravi Salgia , MD

12:15 PM - 12:35 PM

Cased-Based Panel Discussion

Panelists:

Diana Hsu, MD; Ravi Salgia , MD

12:35 PM - 01:35 PMLunch & Product Theater Sponsored by Amgen
01:35 PM - 02:20 PMEducation Forum sponsored by AstraZeneca (Non-CME Accredited)
02:20 PM - 02:50 PMBinaytara's Efforts in Improving Cancer Care Disparities (Non-CME Accredited)
02:50 PM - 03:50 PMSession 4: Toxicity Management

Session Chair: Caroline Maxwell, MSN, FNP

02:50 PM - 03:05 PM

Managing Immune-Related Adverse Events (irAEs) from IO Therapy David Berz, MD

03:05 PM - 03:20 PM

Managing TKI-Related Toxicities

03:20 PM - 03:35 PM

Managing ADC-Related Toxicities

03:35 PM - 03:50 PM

Panel Discussion

Moderators:

Caroline Maxwell, MSN, FNP

Panelists:

David Berz, MD

03:50 PM - 04:20 PMBreak & Exhibits
04:20 PM - 05:20 PMSession 5: Case Discussions: Small Cell, Thymoma, and Mesothelioma

Session Chair: Pamela Mae Miel, MD

04:20 PM - 04:35 PM

SCLC Case

04:35 PM - 04:50 PM

Stage III or IV Thymoma Case Dan Raz, MD

04:50 PM - 05:05 PM

Epithelioid Mesothelioma Case Matthew Gubens, MD, MS

05:05 PM - 05:20 PM

Panel Discussion

Moderators:

Pamela Mae Miel, MD

Panelists:

Dan Raz, MD; Matthew Gubens, MD, MS

Venue and map

Accreditations and continuing education

Accreditation

Registration and pricing